Skip to main content
. 2011 Feb;178(2):525–536. doi: 10.1016/j.ajpath.2010.10.002

Figure 4.

Figure 4

HPGD expression in prostate cancer samples. A: Relative HPGD and AR mRNA expression graphed for primary cancer samples (left). The sample with highest HPGD mRNA expression has undifferentiated histology (right, bottom) and shows cytoplasmic HPGD staining in the cancer cells and weak staining in the stroma (right, top). Inset: Negative control staining (no first antibody). B: Box plot analysis of relative HPGD mRNA expression levels in normal prostate and in primary and advanced prostate cancer samples. The box refers to the quartile distribution range (25% to 75%), with the median indicated by a vertical line. The whiskers indicate the 95% range, and individual outlier samples are also shown. C: Immunohistochemical staining of HPGD in histologically normal (left column) and hyperplastic (right column) prostate tissue samples. D: Immunohistochemical staining of paraffin-mounted tissue microarray sections containing metastatic prostate cancer samples (77 samples from 47 patients) indicate HPGD expression in 62% of the patients (29/47) and 52% of the samples (40/77). Staining shows diffuse and variable cytosolic and nuclear localization of HPGD in the epithelial prostate cancer cells. Staining of four individual samples is shown. Staining of four individual samples is shown, ranging in intensity from − to +++. The magnification scale is identical for all 16 images.